 Cristina Penaranda
Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Host-Pathogen Interactions | 4 | 2021 | 295 | 1.350 |
Why?
| | Pseudomonas aeruginosa | 3 | 2021 | 298 | 0.910 |
Why?
| | Bacterial Infections | 2 | 2019 | 217 | 0.580 |
Why?
| | Adaptation, Physiological | 1 | 2021 | 484 | 0.570 |
Why?
| | T-Lymphocytes, Regulatory | 4 | 2011 | 337 | 0.510 |
Why?
| | Islets of Langerhans | 3 | 2010 | 728 | 0.490 |
Why?
| | Immune Tolerance | 3 | 2012 | 321 | 0.430 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2012 | 3254 | 0.420 |
Why?
| | Immunologic Memory | 2 | 2012 | 313 | 0.410 |
Why?
| | Bacteria | 1 | 2019 | 725 | 0.410 |
Why?
| | Receptors, Interleukin-7 | 1 | 2012 | 25 | 0.400 |
Why?
| | Interleukin-7 | 1 | 2012 | 45 | 0.400 |
Why?
| | CD3 Complex | 1 | 2011 | 92 | 0.370 |
Why?
| | Lymphocyte Depletion | 1 | 2011 | 115 | 0.360 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 383 | 0.360 |
Why?
| | Propylene Glycols | 1 | 2010 | 25 | 0.340 |
Why?
| | Sphingosine | 1 | 2010 | 33 | 0.340 |
Why?
| | T-Lymphocytes | 4 | 2014 | 1735 | 0.330 |
Why?
| | Pseudomonas Infections | 2 | 2021 | 184 | 0.310 |
Why?
| | Autoimmunity | 2 | 2009 | 815 | 0.270 |
Why?
| | Mice, Inbred NOD | 5 | 2012 | 552 | 0.270 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2009 | 615 | 0.270 |
Why?
| | Immunosuppressive Agents | 1 | 2010 | 641 | 0.260 |
Why?
| | Mice | 13 | 2021 | 14847 | 0.240 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1257 | 0.240 |
Why?
| | Animals | 18 | 2021 | 31570 | 0.230 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1519 | 0.220 |
Why?
| | Receptor, IGF Type 1 | 3 | 2007 | 58 | 0.200 |
Why?
| | Signal Transduction | 3 | 2012 | 4501 | 0.200 |
Why?
| | Diabetes Mellitus | 1 | 2010 | 898 | 0.200 |
Why?
| | Intracellular Space | 1 | 2021 | 68 | 0.180 |
Why?
| | Microbial Viability | 1 | 2021 | 79 | 0.180 |
Why?
| | Genetic Fitness | 1 | 2021 | 53 | 0.180 |
Why?
| | Urinary Tract Infections | 1 | 2021 | 131 | 0.170 |
Why?
| | Interferon-gamma | 4 | 2014 | 719 | 0.160 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 285 | 0.160 |
Why?
| | Host-Parasite Interactions | 1 | 2019 | 94 | 0.160 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 4682 | 0.160 |
Why?
| | Chimera | 1 | 2018 | 59 | 0.160 |
Why?
| | RNA, Bacterial | 1 | 2019 | 174 | 0.150 |
Why?
| | Genome, Bacterial | 1 | 2019 | 106 | 0.150 |
Why?
| | Bacterial Physiological Phenomena | 1 | 2019 | 57 | 0.150 |
Why?
| | Embryo, Nonmammalian | 1 | 2018 | 173 | 0.150 |
Why?
| | Embryo, Mammalian | 1 | 2018 | 213 | 0.150 |
Why?
| | Hematopoiesis | 1 | 2018 | 170 | 0.140 |
Why?
| | Mice, Transgenic | 4 | 2011 | 1947 | 0.140 |
Why?
| | Single-Cell Analysis | 1 | 2019 | 185 | 0.140 |
Why?
| | Tuberculosis | 1 | 2019 | 241 | 0.140 |
Why?
| | Mycobacterium tuberculosis | 1 | 2019 | 269 | 0.140 |
Why?
| | Masoprocol | 2 | 2007 | 3 | 0.140 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 388 | 0.130 |
Why?
| | Lymphocyte Activation | 3 | 2012 | 1036 | 0.130 |
Why?
| | Urea | 2 | 2006 | 66 | 0.130 |
Why?
| | Cells, Cultured | 2 | 2021 | 3862 | 0.120 |
Why?
| | Zebrafish | 1 | 2018 | 413 | 0.120 |
Why?
| | Adoptive Transfer | 2 | 2012 | 194 | 0.120 |
Why?
| | Salmonella typhimurium | 1 | 2015 | 165 | 0.110 |
Why?
| | DNA-Binding Proteins | 2 | 2011 | 1311 | 0.110 |
Why?
| | Bacteroides fragilis | 1 | 2013 | 11 | 0.110 |
Why?
| | Galactosylceramides | 1 | 2013 | 22 | 0.110 |
Why?
| | Transcriptome | 1 | 2019 | 721 | 0.110 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2012 | 193 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2010 | 960 | 0.110 |
Why?
| | Macrophages | 3 | 2015 | 1259 | 0.100 |
Why?
| | Regeneration | 1 | 2014 | 158 | 0.100 |
Why?
| | RNA, Messenger | 1 | 2019 | 2550 | 0.100 |
Why?
| | Antigens, Differentiation | 1 | 2012 | 79 | 0.100 |
Why?
| | Pancreas | 1 | 2014 | 276 | 0.100 |
Why?
| | Autoimmune Diseases | 2 | 2011 | 381 | 0.090 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 1144 | 0.090 |
Why?
| | Interleukin-2 | 2 | 2009 | 413 | 0.090 |
Why?
| | Thymus Gland | 1 | 2011 | 296 | 0.090 |
Why?
| | Transcription Factors | 2 | 2011 | 1526 | 0.090 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2011 | 160 | 0.090 |
Why?
| | Fingolimod Hydrochloride | 1 | 2010 | 29 | 0.080 |
Why?
| | Immunity, Innate | 1 | 2014 | 720 | 0.080 |
Why?
| | Forkhead Transcription Factors | 1 | 2009 | 170 | 0.080 |
Why?
| | Lymphocytes | 1 | 2010 | 327 | 0.080 |
Why?
| | Graft Rejection | 1 | 2011 | 511 | 0.070 |
Why?
| | Immunotherapy | 1 | 2011 | 473 | 0.070 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2007 | 36 | 0.070 |
Why?
| | Autoantigens | 1 | 2009 | 396 | 0.070 |
Why?
| | Combinatorial Chemistry Techniques | 1 | 2006 | 16 | 0.070 |
Why?
| | Breast Neoplasms | 3 | 2007 | 1846 | 0.070 |
Why?
| | Aminoquinolines | 1 | 2006 | 19 | 0.070 |
Why?
| | Cell Line | 1 | 2011 | 2629 | 0.060 |
Why?
| | Phenylurea Compounds | 1 | 2006 | 81 | 0.060 |
Why?
| | Female | 5 | 2021 | 59347 | 0.060 |
Why?
| | Mice, Knockout | 1 | 2010 | 2563 | 0.060 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2005 | 286 | 0.050 |
Why?
| | Receptor, ErbB-2 | 1 | 2005 | 300 | 0.050 |
Why?
| | Humans | 8 | 2019 | 114077 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2006 | 784 | 0.040 |
Why?
| | Apoptosis | 2 | 2006 | 2349 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2003 | 435 | 0.040 |
Why?
| | Nucleic Acid Hybridization | 1 | 2019 | 187 | 0.040 |
Why?
| | Genes, Essential | 1 | 2019 | 18 | 0.040 |
Why?
| | Blastula | 1 | 2018 | 3 | 0.040 |
Why?
| | Cell Fusion | 1 | 2018 | 50 | 0.040 |
Why?
| | Cell Tracking | 1 | 2018 | 13 | 0.040 |
Why?
| | DNA Transposable Elements | 1 | 2019 | 97 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2005 | 2173 | 0.040 |
Why?
| | Coloring Agents | 1 | 2018 | 72 | 0.040 |
Why?
| | Transplantation, Heterologous | 1 | 2018 | 180 | 0.040 |
Why?
| | Larva | 1 | 2018 | 191 | 0.040 |
Why?
| | Neoplasms | 1 | 2011 | 2088 | 0.040 |
Why?
| | Bone Marrow Cells | 1 | 2018 | 266 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2018 | 126 | 0.040 |
Why?
| | Bone Marrow Transplantation | 1 | 2018 | 237 | 0.040 |
Why?
| | Cell Lineage | 1 | 2018 | 308 | 0.030 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2015 | 60 | 0.030 |
Why?
| | Cell Line, Tumor | 3 | 2007 | 2699 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 595 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2006 | 1875 | 0.030 |
Why?
| | Young Adult | 1 | 2010 | 10458 | 0.030 |
Why?
| | Salmonella Infections | 1 | 2015 | 50 | 0.030 |
Why?
| | Ceruletide | 1 | 2014 | 4 | 0.030 |
Why?
| | Acinar Cells | 1 | 2014 | 12 | 0.030 |
Why?
| | Interferon Type I | 1 | 2015 | 128 | 0.030 |
Why?
| | Cell Dedifferentiation | 1 | 2014 | 28 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 863 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2014 | 157 | 0.030 |
Why?
| | Macrophage Activation | 1 | 2014 | 163 | 0.030 |
Why?
| | Natural Killer T-Cells | 1 | 2013 | 63 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2015 | 813 | 0.020 |
Why?
| | Adolescent | 1 | 2010 | 17811 | 0.020 |
Why?
| | Receptor Cross-Talk | 1 | 2011 | 20 | 0.020 |
Why?
| | CD28 Antigens | 1 | 2011 | 47 | 0.020 |
Why?
| | B7-1 Antigen | 1 | 2011 | 53 | 0.020 |
Why?
| | Child | 1 | 2010 | 18408 | 0.020 |
Why?
| | CTLA-4 Antigen | 1 | 2011 | 76 | 0.020 |
Why?
| | Antigen-Presenting Cells | 1 | 2011 | 150 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2014 | 465 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2011 | 170 | 0.020 |
Why?
| | Complementarity Determining Regions | 1 | 2009 | 43 | 0.020 |
Why?
| | Neutrophils | 1 | 2014 | 1089 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2014 | 763 | 0.020 |
Why?
| | CpG Islands | 1 | 2009 | 118 | 0.020 |
Why?
| | Interleukin-17 | 1 | 2009 | 104 | 0.020 |
Why?
| | Antigens, CD | 1 | 2011 | 440 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2009 | 274 | 0.020 |
Why?
| | Luminescent Proteins | 1 | 2009 | 166 | 0.020 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 66 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 211 | 0.020 |
Why?
| | Cricetulus | 1 | 2006 | 97 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 338 | 0.020 |
Why?
| | CHO Cells | 1 | 2006 | 137 | 0.020 |
Why?
| | Cricetinae | 1 | 2006 | 252 | 0.020 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2006 | 64 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2008 | 415 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2009 | 1981 | 0.020 |
Why?
| | Animals, Genetically Modified | 1 | 2006 | 215 | 0.020 |
Why?
| | DNA Methylation | 1 | 2009 | 493 | 0.020 |
Why?
| | Cell Survival | 1 | 2008 | 1014 | 0.010 |
Why?
| | Caspases | 1 | 2006 | 243 | 0.010 |
Why?
| | Neoplasms, Experimental | 1 | 2005 | 149 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2009 | 2783 | 0.010 |
Why?
| | Cell Division | 1 | 2006 | 754 | 0.010 |
Why?
| | Inflammation | 1 | 2014 | 2465 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 2003 | 136 | 0.010 |
Why?
| | 3T3 Cells | 1 | 2003 | 140 | 0.010 |
Why?
| | Mutation | 1 | 2013 | 3338 | 0.010 |
Why?
| | T-Box Domain Proteins | 1 | 2003 | 92 | 0.010 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 140 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2005 | 1218 | 0.010 |
Why?
| | Antigens | 1 | 2003 | 317 | 0.010 |
Why?
| | Phosphorylation | 1 | 2005 | 1559 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 787 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 924 | 0.010 |
Why?
| | Blotting, Western | 1 | 2003 | 1143 | 0.010 |
Why?
| | Up-Regulation | 1 | 2003 | 802 | 0.010 |
Why?
| | Male | 1 | 2018 | 55418 | 0.010 |
Why?
| | Time Factors | 1 | 2003 | 6077 | 0.010 |
Why?
|
|
Penaranda's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|